NRSN

Neurosense Therapeutics Ltd

• Dow Jones·5d ago

  NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital

• Dow Jones·5d ago

  NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital

• TipRanks·6d ago

  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)

• TipRanks·04/06 13:56

  NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC

• Benzinga·04/06 13:21

  NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'

• Reuters·04/06 13:20

  NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

• PR Newswire·04/06 13:20

  NeuroSense Granted Brazilian Patent Covering PrimeC Composition

• Benzinga·04/06 07:19

  Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026

• Seeking Alpha·04/03 14:54

  NeuroSense Therapeutics receives Nasdaq notices over listing requirements

• Reuters·04/03 14:03

  NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement

• TipRanks·04/03 13:47

  NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status

• TipRanks·04/02 12:46

  Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM

• Reuters·04/01 20:25

  NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership

• TipRanks·04/01 13:56

  Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)

• TipRanks·03/31 21:22

  NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial